Clinical Trials
27 trialsA Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Janssen Research & Development, LLC
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Washington University School of Medicine
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Baylor College of Medicine
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
National Institutes of Health Clinical Center (CC)
DS-3201b in Participants With Lymphomas
Daiichi Sankyo
INVISE
Gilead Sciences
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
Memorial Sloan Kettering Cancer Center
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
CRETI-NH
Baylor College of Medicine
Venetoclax Plus Inotuzumab for B-ALL
Dana-Farber Cancer Institute
CD22 Redirected Autologous T Cells for ALL
University of Pennsylvania
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
LONCA
Medical College of Wisconsin
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
City of Hope Medical Center
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
Thomas Jefferson University
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Genmab
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
University of Chicago
ENABLE-1
Malaghan Institute of Medical Research
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Cullinan Therapeutics Inc.